

Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	----------------------------------	---	--	---

Service Category

- | | |
|--|---|
| <input type="checkbox"/> Anesthesia | <input type="checkbox"/> Medicine Services and Procedures |
| <input type="checkbox"/> Surgery | <input type="checkbox"/> Evaluation and Management Services |
| <input type="checkbox"/> Radiology Procedures | <input type="checkbox"/> DME/Prosthetics or Supplies |
| <input type="checkbox"/> Pathology and Laboratory Procedures | <input checked="" type="checkbox"/> Part B Drugs |

Service Description

This document addresses the use of *Elotuzumab (Empliciti®)*, a SLAMF7-directed immunostimulatory antibody approved by the Food and Drug Administration (FDA) for the treatment of certain patients with multiple myeloma.

Background Information

Empliciti is a humanized IgG1 monoclonal antibody that targets the signaling lymphocytic active molecule (SLAM) family member F7 (SLAMF7) protein expressed on myeloma and natural killer cells. Empliciti activates natural killer cells mediating the killing of myeloma cells through antibody-dependent cellular cytotoxicity. Empliciti is used to treat multiple myeloma.

The FDA-approved indications for Empliciti include use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in individuals who have received one to three prior therapies. It is also FDA-approved in combination with pomalidomide and dexamethasone, in individuals who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. The trials used to approve these two indications included patients with relapsed, refractory, or progressive disease. The National Comprehensive Cancer Network® (NCCN) provides additional recommendations with a category 2A level of evidence for use in combination with bortezomib and dexamethasone for previously treated myeloma for relapsed or progressive disease.

Definitions and Measures

- Multiple myeloma: A type of cancer that begins in plasma cells (white blood cells that produce antibodies).
- Plasma cell leukemia: A rare and aggressive form of multiple myeloma characterized by high levels of plasma cells in the peripheral blood.
- Progressive disease: For cancer, disease that is growing (e.g. growth in size of tumor), spreading, or worsening.

Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	---	--	--	---

- Proteasome inhibitors: A class of drugs used to treat multiple myeloma that work by blocking the action of proteasomes which are cellular complexes that break down proteins. Examples include bortezomib, carfilzomib and ixazomib.
- Refractory disease: Illness or disease that does not respond to treatment.
- Relapse: After a period of improvement, the return of signs and symptoms of cancer.

Approved Indications

Elotuzumab (Empliciti®) is indicated:

- In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies.
- In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Other Uses

- A. None

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

HCPCS	Description
J9176	Injection, elotuzumab, 1 mg [Empliciti]

ICD-10	Description
C90.00-C90.32	Multiple myeloma and malignant plasma cell neoplasms
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	----------------------------------	---	--	---

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member’s medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Elotuzumab (Empliciti®)

A. Criteria For Initial Approval *(Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient’s diagnosis for the drug and confirming that the patient has met **all** approval criteria.)*

- i. Individual has a diagnosis of relapsed, progressive, or refractory multiple myeloma, including plasma-cell leukemia; **AND**
- ii. Disease is relapsed, progressive, or refractory following at least one prior therapy; **AND**
- iii. Individual is using in combination with one of the following:
 - A. Lenalidomide and dexamethasone; **OR**
 - B. Bortezomib and dexamethasone (NCCN 2A); **OR**
 - C. Pomalidomide and dexamethasone (in individuals who have received at least two prior therapies including lenalidomide and a proteasome inhibitor).

B. Criteria For Continuation of Therapy

- i. MMM considers continuation of Elotuzumab (Empliciti®) therapy medically necessary in members requesting reauthorization for an indication listed in Section A above (Criteria for Initial Approval) when there is no evidence of an unacceptable toxicity or disease progression while on the current regimen. The following information should be submitted for reauthorization:
 - A. A current oncology note documenting the patient’s response to treatment showing no progression of disease.
 - B. Current imaging studies and other objective measures, as appropriate, showing no progression of disease when compared with previous results

C. Authorization Duration

- i. Initial Approval Duration: Per cycle
- ii. Reauthorization Approval Duration: Up to 6 months

D. Conditions Not Covered

Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	----------------------------------	---	--	---

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Requests for Empliciti (elotuzumab) may not be approved when the above criteria (Section A: Criteria for Initial Approval) are not met and for all other indications.

Limits or Restrictions

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

- i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Recommended Treatment	Dosing Recommendations ^a	Recommended Duration
Used in combination with Lenalidomide and Dexamethasone	<ul style="list-style-type: none"> • Cycles 1 and 2 (28-days cycle): 10 mg/kg weekly (on Days 1, 8, 15, and 22) • Cycle 3 and following cycles (28-days cycle): 10 mg/kg every 2 weeks 	Until disease progression or unacceptable toxicity
Used in Combination with Pomalidomide and Dexamethasone	<ul style="list-style-type: none"> • Cycles 1 and 2 (28-days cycle): 10 mg/kg weekly (on Days 1, 8, 15, and 22) • Cycle 3 and following cycles (28-days cycle): 20 mg/kg every 4 weeks 	Until disease progression or unacceptable toxicity
Notes		
<ul style="list-style-type: none"> • Empliciti injection available dosage form & strengths: 300 mg or 400 mg single-dose vial 		

^a Premedication must include dexamethasone, diphenhydramine, ranitidine and acetaminophen

Reference Information

Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	----------------------------------	---	--	---

1. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
2. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2024; Updated periodically.
3. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed: February 3, 2026.
 - a. Multiple Myeloma. V5.2026. Revised December 8, 2022.
4. UpToDate. (n.d.). Elotuzumab: Drug information. Retrieved February 3, 2026, from https://www.uptodate.com/contents/elotuzumab-drug-information?search=empliciti&source=panel_search_result&selectedTitle=1~15&usage_type=panel&kp_tab=drug_general&display_rank=1#F45755764
5. Bristol-Myers Squibb. (n.d.). Empliciti® (elotuzumab) [Prescribing Information]. Retrieved February 3, 2026, from https://packageinserts.bms.com/pi/pi_empliciti.pdf

Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Medical Policy



Utilization Management and Clinical Medical Policy

Policy Name: Elotuzumab (Empliciti®)	Policy Number: MP-RX-FP-26-23	Scope: <input checked="" type="checkbox"/> MMM MA <input checked="" type="checkbox"/> MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 03/24/2026	Effective Date: 03/24/2026 Frequently Revision: Annual
--	---	--	--	---

Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Annual Review	Added available dosage forms and strengths. Coding reviewed: no changes. Minor formatting changes. References updated.	3/17/2026	03/24/2026
Annual Review	Minimal changes; Word formatting. No coding updates.	6/9/2025	6/19/2025
Annual Review	Clarify line of therapy to require at least one prior treatment per label/NCCN. Add therapeutic alternatives section and federal statement. Wording and formatting changes. Coding Reviewed: No changes.	2/18/2025	3/6/2025
Focus Review	Update statement for criteria for initial approval: Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met all approval criteria.	3/25/2024	5/9/2024
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023